Skip to main content

Year: 2021

Prominent European University Validates “Global Warming Solutions” Revolutionary and Patented “Sodium Battery Technology”

Temecula, CA, Nov. 23, 2021 (GLOBE NEWSWIRE) — Global Warming Solutions, Inc., (OTC MARKETS: “GWSO”), a worldwide developer of technologies that help mitigate Global Warming and its effects on the planet announces that a Prominent European University’s Department of Chemistry has successfully conducted a Third-Party Testing & Analysis of the Technology surrounding “GWSO’s hybrid hydrogen production system.” This system includes high-energy Sodium battery and hydrogen system which can generate hydrogen during electrolysis and then can generate energy as a fuel cell. “The voltage across the sodium battery 40 Ohm load was 3 Volts per cell. The test has been contacted with one cell and with batteries with voltage 12 Volts. Scientifically, the results of the measurements during the charge/discharge of the system showed good stability...

Continue reading

HealthTab™ to Offer Abbott’s i-STAT Alinity™, Expanding Chronic Disease Testing to Select Community Pharmacies in Canada

VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) — Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to announce the signing of a non-exclusive, pilot supplier distribution agreement in Canada between HealthTab™ Inc., a wholly owned subsidiary, and Abbott, the global healthcare company, with respect to the handheld blood chemistry analyzer, i-STAT Alinity. The agreement allows HealthTab to distribute Abbott’s point-of-care i-STAT Alinity and its associated tests for creatinine in Canadian pharmacies to better support patients with important information about their renal function. “Understanding renal function in patients at risk from or already living with chronic disease is critical,” said Hector Bremner, CEO of Avricore Health. “With i-STAT Alinity and its associated test...

Continue reading

InMed Pharmaceuticals to Participate in Cowen’s 4th Annual Cannabis Conference

VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that InMed’s management team is scheduled to participate in Cowen’s 4th Annual Cannabis Conference to be held virtually on November 29 – December 1, 2021. Cowen’s 4th Annual Cannabis Conference Date: November 29 – December 1, 2021 Management will be available for virtual one-on-one meetings with institutional and corporate clients of the firm. To request 1-on-1 meetings with the Company, please contact your Cowen institutional representative or visit the conference website at https://www.cowen.com/conferences-and-events/4th-annual-cannabis-conference/ Cowen’s 4th Annual Cannabis Conference...

Continue reading

First Tellurium Recruits First Solar’s Previous Exploration Manager and Veteran Geologist John Keller to Advisory Board

Mr. Keller is Appointed Project Manager of the Klondike Tellurium Property VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) — First Tellurium Corp. (CSE: FTEL) (the “Company” or “First Tellurium”), is pleased to introduce veteran Certified Professional Geologist John Keller who has joined the company’s advisory board and will manage exploration and development of its Klondike tellurium property in Colorado. The largest use of tellurium (Te) in the past decade or more has been in the manufacture of thin-film photovoltaic solar panels. Tellurium, along with cadmium, is an essential component of the thin photovoltaic layer which generates the electricity from solar radiation. First Solar is one of the world’s largest manufacturers of solar panels with a market cap of nearly USD 12 Billion and trades on the NASDAQ market....

Continue reading

Ceylon Graphite’s Anode Graphite in Full Cell Lithium Ion Batteries Outperforms Leading Commercial Synthetic Graphite

Ceylon Graphite completes full cell testing at University College London (UCL) Ceylon’s unique natural vein graphite material has outperformed an Industry Standard synthetic graphite- CYL discharge capacity of 165 mAh/g, as compared to the Industry Standard of 153mAg/g Very small loss in capacity on 50 cycles We believe that the impressive performance of our vein graphite material is due toHigh crystallinity of vein graphite High purity and further purification technology CYL proprietary coating and spherodizing technologyCeylon has a mine to battery strategy that will mazimize the value of our high grade Sri Lankan vein graphite by transforming into anode graphite for the rapidly growing lithium ion battery market.VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) — Ceylon Graphite Corp. (“Ceylon Graphite”) (TSX-V:...

Continue reading

MediPharm Labs Expands CBN Portfolio with Two New Products

A leader in CBN products, MediPharm Labs, adds CBN:CBD products to its wellness portfolio for consumers and patients looking for a product without THC effects. New CBN products include CBN:CBD 1:2 Relax Formula Oil and a Northbound high CBN and high CBD vape cartridge.BARRIE, Ontario, Nov. 23, 2021 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the expansion of its unique cannabinol (“CBN”) product line. “Once again MediPharm Labs continues to innovate and commercialize unique cannabinoids. Our exciting new CBN:CBD is a unique formulation that allows consumers a CBN product without the effects of THC. This is an exciting addition to our wellness line of products which...

Continue reading

Company Announcement 15/2021

November 23, 2021 NORDIC SHIPHOLDING A/SCompany Announcement: 15/2021 Published via NASDAQ OMX on November 23, 2021Revised Outlook for 2021 Assuming the Company’s three vessels remain in the Hafnia Handy Pool and Hafnia LR Pool, respectively, for the rest of the year, the TCE revenue for 2021 is now expected to be in the region of USD 8.5 million – USD 10.5 million, down from USD 9.0 million – USD 11.0 million as previously forecasted. After accounting for operating expenditure budgeted by the respective technical managers, the Group’s expected EBITDA (earnings before interest, tax, depreciation and amortisation) for 2021 is expected to be in the range of USD -1.0 million – USD 1.0 million (previous forecast was USD NIL million – USD 2.0 million). The result before tax is now forecasted at USD -9.5 million – USD -7.5 million, compared...

Continue reading

The New Generation Gap: Nationwide Survey Finds Different Perspectives on Anxiety Between Parents, Young Adults

GeneSight Mental Health Monitor finds many parents struggle to know the difference between teenage behavior and a mental health challenge SALT LAKE CITY, Nov. 23, 2021 (GLOBE NEWSWIRE) — One of the biggest issues parents of teenagers may face is determining if their child is experiencing a mental health challenge or ordinary “growing pains.” Only half of parents* with children ages 16 to 24 said they are very or completely confident they can tell the difference between normal adolescent challenges and a mental health condition, according to the GeneSight® Mental Health Monitor from Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine. Further, nearly one in three parents believe that “anxiety” and “worry” are the same thing. “Anxiety and worry are not the same thing. Worry is situational. Anxiety...

Continue reading

COMPASS Pathways granted fifth US patent for crystalline psilocybin

London, UK – 23 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office (USPTO). This is COMPASS’s 10th patent overall, with five now granted in the US, two in the UK, one in Germany and two in Hong Kong. The new patent, US Patent No 11,180,517, covers methods of treating treatment-resistant depression (TRD) with crystalline psilocybin as well as with oral dosage forms of crystalline psilocybin with an excipient. Crystalline psilocybin is used in COMP360, COMPASS’s synthesised psilocybin formulation being developed for psilocybin therapy in TRD. George Goldsmith, CEO and Co-founder, COMPASS Pathways, said: “This...

Continue reading

Esa Peltola appointed as CEO of Nordic Rescue Group

Sievi Capital Plc Press Release 23 November 2021 at 2.00 pm EET Esa Peltola appointed as CEO of Nordic Rescue Group  Nordic Rescue Group’s CEO Matti Huttunen is leaving the company. Nordic Rescue Group’s Board of Directors has appointed Esa Peltola as the new CEO. Peltola has extensive industry experience. Among other things, Peltola has previously worked as the CEO of Bronto Skylift, and is also one of the founders of Vema Lift. “Esa Peltola is extremely competent in successful business development. I am happy to be appointing Esa to lead the organisation and implement the company’s strategy,” says Carl Haglund, Chair of the Board of Directors at Nordic Rescue Group. “Esa Peltola will be an excellent CEO for Nordic Rescue Group. He has strong industry expertise, diverse work experience and excellent track record of world-class business...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.